



CIN No: L24239MH1987PLC043662

Date: 24th August, 2022

To

BSE Ltd.

Listing Department
Phiroze jeejeebhoy Towers,
Dalal street- Fort
Mumbai-40001

Ref: BSE Scrip Code: 539730

Subject: Announcement under Regulation 30 of SEBI (LODR) Regulations, 2015

Dear Sir/ Madam,

Please find enclosed herewith information required under Regulation 30 of SEBI (LODR) Regulations, 2015:

“Business Update of Fredun Pharmaceuticals Limited”

We request you to take the above information on your records.

Thanking you,

For **Fredun Pharmaceuticals Limited**



Jinkal Shah
Company Secretary and Compliance Officer
Membership No: A40722

Encl: a/a

Registered Office: Manoj Industrial Premises, G.D. Ambekar Marg, Wadala (W), Mumbai - 400 031, (INDIA)

Corporate Office: Urmi Estate, 11th Floor, Ganpatrao Kadam Marg, Lower Parel (W), Mumbai - 400013.

Phone No.: 91-22- 4031 8111 **Fax:** 91-22-4031 8133

Factory: 14,15,16, Zorabian Industrial Complex, Vevoor, Palghar (E), Dist: Palghar - 401 404.

Phone No.: +917045957828, +917045957829, +917045957830, +917045956857

E-Mail: business@fredungroup.com **Web:** www.fredungroup.com



FREDUN PHARMACEUTICALS LIMITED

PRESS RELEASE

Business Update

Mumbai, India | August 23, 2022

Fredun Pharmaceuticals Limited (BSE: 539730), is a diversified healthcare provider, having unique range of products in various segments. The company achieved higher than target profits for the first quarter of FY23.

Key Business Highlights

Generics

- Launched **Twenty eight new products** in Southeast Asia
- Government supplies have crossed Rs.85 Lacs/month and **likely to reach Rs.145 Lacs/month by Oct'22**
- Started work on state-of-the-art on Bone Graft manufacturing unit, **scheduled for completion by May'23**. This plant has the capability to cater to the Global market for the next seven years.
- Out of the 180 Registrations expected in CY22, we have received 67 till now and on target to get the rest by end of this year.
- 44 new products of FREDUN Gx will be sold for the first time in Sept'22 and another 31 new products will be launch by Oct'22

Animal Healthcare

- **27 new pharmaceutical Veterinary products** are ready for launch in second week of Sept'22

Cosmeceuticals

- New department of medicated Lotion manufacturing **completed successful trials in June'22**. First order for **seven million bottles** is under execution, and expected to be completed by end of Oct'22.
- Newly inaugurated medicated Balm manufacturing division has also **successfully executed its first order of one million bottles**, it will be dispatched in the first week of Sept'22.

Nutraceuticals

- Signed annual export contracts for **four new nutraceutical products in MENA Region**
- Successful launch of Nutraceutical products in Africa will help the company achieve its targeted Sales number for Nutraceuticals

About Fredun Pharmaceuticals

Fredun Pharmaceuticals Limited is a pharmaceutical company primarily engaged in the business of pharmaceuticals and healthcare. It offers a range of products, including antihypertensives, antidiabetic, antiretroviral drugs (ARVs) and narcotics. It is also engaged in the manufacturing of dietary/herbal supplements, nutraceuticals, and other healthcare products along with animal healthcare products. With such a diverse range of products, the Company's objective is to be a holistic healthcare provider. The Company primarily exports its products to Africa, Southeast Asia, Commonwealth of Independent States (CIS) countries and Latin America.



FREDUN PHARMACEUTICALS LIMITED

Over the last few years we have worked extensively to increase our capacities and create a product mix which helps us drive growth for the next decade.

Our margins will significantly improve over the next few years based on our investments in the last few quarters.

For further details, please feel free to contact:

Investor Relations team at Fredun Pharmaceuticals Limited

Fredun Medhora

Managing Director, Fredun Pharmaceuticals Ltd

P: 022-4031 8111

E: investing@fredungroup.com

Registered Office

26, Manoj Industrial Premises,

G.D. Ambedkar Marg, Wadala,

Mumbai – 400 031

Diwakar Pingle

Ernst & Young LLP

P: 022-6129 0000

E: diwakar.pingle@in.ey.com

Corporate Office

'Urmi Estate', 11th Floor,

Ganpatrao Kadam Marg, Lower Parel (W),

Mumbai – 400 013

Tel. No.: +91 22 4031 8111

Disclaimer:

This press release may include statements of future expectations and other forward-looking statements based on management's current expectations and beliefs concerning future developments and their potential effects upon Fredun and its subsidiaries/associates. These forward-looking statements involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Forward-looking statements are provided to allow potential investors the opportunity to understand management's beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them. Important factors that could cause actual results to differ materially from our expectations include, amongst other: general economic and business conditions in India, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, change in laws and regulations that apply to pharmaceuticals, increasing competition in and changes in political conditions in India. Neither Fredun, nor our Directors, or any of our subsidiaries/associates assume any obligation to update any particular forward-looking statement contained in this release. The Company undertakes no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.